Navigation Links
China Medicine Announces Record Fourth Quarter and Fiscal Year 2007 Results

-- FY 07 revenues grow 75% to $42.1 million -- FY 07 earnings up 43% to $6.9 million or 50 cents per diluted share

GUANGZHOU, China, March 27 /Xinhua-PRNewswire/ -- China Medicine Corporation (OTC Bulletin Board: CHME) ("China Medicine" or "the Company"), a leading distributor and developer of prescription and over the counter pharmaceuticals, traditional Chinese medicines (TCM), nutritional and dietary- supplements, medical devices, and medical formulations in the PRC, today reported record financial results for the fourth quarter and fiscal year ended December 31, 2007.

Fourth Quarter 2007 Highlights

-- Revenues increased 89% from Q4 of 2006, to $16.2 million

-- Gross profit increased 30% from Q4 of 2006, to $4.5 million

-- Operating income increased 15% from Q4 of 2006, to $3.4 million

-- Net Income increased 15% from Q4 of 2006, to $2.8 million

Full Year 2007 Highlights

-- Total revenues increased 75% to $42.1 million

-- Gross profit increased 38% to $12.4 million

-- Operating income increased 36% to $8.4 million

-- Net income increased 43% to $6.9 million, or $0.50 per diluted share

-- Obtained regional distribution rights to 774 new products in

Guangdong Province

-- Received RMB 800,000 in grants for aflatoxin detoxifizyme ("ADTZ")

project from Education Department of Guangdong Province

"This was a very successful year for China Medicine, both in terms of financial performance and the execution of our business strategy. Our very strong revenue growth was driven by an expanded number of pharmaceutical products provided by our suppliers, as well as increased sales of our self- developed medical formulations and other intellectual property relating to pharmaceutical product development," said Mr. Senshan Yang, China Medicine's Chairman and CEO.

"In 2007, we expanded our distribution network to cover both municipal and rural 607,500

Amortization of stock option

compensation 154,470 86,521

Amortization of deferred expenses 325,687 --

Loss from investment -- 110,982

Change in operating assets and


Accounts receivable, trade (5,879,829) (4,514,763)

Inventories (1,840,170) (498,624)

Advances to suppliers (2,535,589) (2,933,832)

Other current assets (34,728) (129,096)

Accounts payable, trade (120,129) 17,275

Other payables - related parties (30,000) 30,000

Other payables and accrued

liabilities 45,119 (73,246)

Customer deposits 176,763 (19,140)

Taxes payable 145,730 121,850

Liquidated damages payable -- 44,003

Net cash used in operating

activities (2,310,113) (2,218,208)



Purchase of equipment (389,588) (825,787)

Purchase of intangible asset -- (703)

Net cash used in investing

activities (389,588) (826,490)



Payments on short-term loans -- (94,094)

Proceeds from issuance of preferred

stock -- 3,783,000

Payments for reverse acquisition -- (32,398)

Proceeds from exercise of warrants

and options 7,829,681 --

Cash paid on shares redeemed -- (167,602)

Net cash provided by financing

activities 7,829,681 3,488,906


INCREASE IN CASH 5,396,293 279,516

CASH, beginning of year 371,480 91,964

CASH, end of year $5,767,773 $371,480

For more information, please contact:

Company Contact:

Ms. Huizhen Yu

Chief Financial Officer

China Medicine Corp

Tel: +86-20-8739-1718


Investor Relations Contact:

Mr. Crocker Coulson


CCG Elite Investor Relations

Tel: +1-646-213-1915 (NY Office)


areas of Guangdong Province in China, to support the Chinese government's recent policy to promote healthcare coverage among the rural and low-income population. In the short term, our expansion to cover these new markets resulted in a reduction in our gross margins as we increased sales of lower-cost over-the-counter pharmaceutical and TCM products. However, as spending on rural healthcare continues to increase, we believe that the rural markets have tremendous potential as increasing funding and an aging population drive demand for more advanced pharmaceutical products."

Fourth Quarter 2007 Results

China Medicine's total revenues in the fourth quarter were $16.2 million, an increase of 89% over the fourth quarter of 2006. This was attributed to a 112% increase in product sales, primarily driven by the increase in over-the- counter product sales made through the company's newly expanded distribution network to municipal and rural areas of Guangdong Province. Product sales totaled $14.7 million and accounted for 91% of total net revenues. Sales of prescription products accounted for 59%, and over-the-counter medicines accounted for 31%, of total revenues during the quarter. Medical formula sales accounted for the remaining 9% of total revenues, totaling $1.5 million, down 10% from the same quarter of 2006. This decline was due to stricter regulation by the State Food and Drug Administration, which must approve every transfer of ownership of a medical formula in China, and which recently increased the complexity of its approval process.

Gross profit in the fourth quarter of 2007 was $4.5 million, an increase of 30% over the fourth quarter of 2006. Gross margin was 28% of total revenues, down from 40% of total revenues in the fourth quarter of 2006. The decline in gross margin was due to higher sales of over-the-counter products, which have lower profit margins than prescription products, and the costs of expansion of the Company's distribution network to rural areas of China in 2007.

Operating expenses in the fourth quarter of 2007 were $1.1 million, up 120% from $0.5 million in the fourth quarter of 2006. This increase was due to higher selling, general and administrative expenses caused by increased public company expenses, higher salaries and employee sales bonuses, as well as the amortization of non-cash expenses from incentive options, increased advertising, trade-show and marketing expenses, and the costs of setting up a distribution network to cover the rural areas of Guangdong Province. The Company does not expect significant increases in selling, general and administrative expenses over the next several quarters.

Operating expenses represented 7% of total revenues in the fourth quarter of 2007, up from 6% in the fourth quarter of 2006.

The Company recorded $214,541 in research and development expenses in the fourth quarter of 2007, compared to $23,378 in the fourth quarter of 2006. The significant increase was primarily due to the pre-clinical study of Yutian Capsule, a traditional Chinese medicine designed for use in the treatment of lung cancer.

Operating income was $3.4 million in the fourth quarter of 2007, up 15% from $2.9 million in fourth quarter of 2006. Operating margin was 21%, as compared to 34% a year ago.

Net income for the fourth quarter of 2007 was $2.8 million, or $0.17 per diluted share, compared to $2.4 million, or $0.31 per diluted share in the fourth quarter of 2006. Earnings per share reflect an additional 8.2 million diluted weighted average shares, primarily due to the exercise of warrants and options in 2007, which generated $7.8 million in gross proceeds to the Company.

Full Year 2007 Results

For the full year 2007, total revenues were $42.1 million, up 75% from $24.0 million in 2006. Approximately 93% of revenue came from product sales and 7% came from medical formula sales. Gross profit for the full year 2007 was $12.4 million, an increase of 38% from $9.0 million in 2006. Gross profit margin was 29% in 2007, a decrease from 37% in 2006. Operating income was $8.4 million, up 36% from $6.2 million in 2006. Operating margin was 20%, as compared to 26% in 2006. Net income for 2007 was $6.9 million or $0.50 per diluted share, compared to $4.8 million or $0.63 per diluted share in 2006. Earnings per share reflect an additional 6.0 million diluted weighted average shares, primarily due to the exercise of warrants and options in 2007.

Financial Condition

As of December 31, 2007, China Medicine had $5.8 million in cash and cash equivalents, and approximately $28.5 million in working capital, an increase of 140% from $11.9 million in 2006. For the year ended December 31, 2007, China Medicine used $2.3 million in cash from operations, due to the increase of advances to suppliers and inventories required to support higher sales. China Medicine also received $7.8 million in proceeds from the exercise of warrants and options. Stockholders' equity as of December 31, 2007 was $30.8 million, an increase of 132% over the $13.3 million recorded as of December 31, 2006.

2008 Outlook

"During 2008 we expect to see continued solid growth in sales, along with improving margins as we leverage our expanded distribution footprint, expand sales of higher margin exclusive products, and see a growing contribution from sales of our proprietary medical formulations," said Mr. Yang. "We are very encouraged by the contribution of our R&D partnerships to building a strong new product pipeline, and expect to report significant clinical milestones over the course of 2008. We are also focused on moving our novel ADTZ product into commercialization this year, and expect to obtain our production permit for the treatment of animal feed and begin trial sales in 2008. If we are successful, this would set us up to begin recognizing meaningful revenues from ADTZ in 2009 and could be an important driver for the Company's future growth. Finally, China Medicine continues to evaluate opportunities to acquire a pharmaceutical manufacturing facility to strengthen our competitive position and achieve vertical integration for our proprietary products, while enhancing our overall profitability," concluded Mr. Yang.

Based on China Medicine's expectations of continued strong demand in the pharmaceutical market, the company expects to achieve revenue growth in the range of approximately 25-35%, gross margins in the range of 30-35%, and approximately 20-22% growth in net income for the full year of 2008.

Conference Call

China Medicine will hold its fourth quarter conference call for all interested persons at 9:00 a.m. Eastern Time on March 27, 2008 to discuss its results. To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 888- 419-5570. International callers should dial 617-896-9871. When prompted by the operator, mention conference passcode 25022850. If you are unable to participate in the call at its scheduled time, a replay will be available for seven days starting on Thursday, March 27 at 11:00 a.m. Eastern Time. To access the replay, dial 888-286-8010 (international callers dial 617-801-6888), and enter the passcode 92139283.

About China Medicine Corporation

China Medicine Corporation is a leading pharmaceutical company which discovers and develops medical formulations and distributes over 2,200 pharmaceutical products in China including prescription and over the counter ("OTC") drugs, traditional Chinese medicine products, herbs and dietary- supplements. The Company distributes the products to wholesale distributors in 28 provinces, more than 300 hospitals, 500 medicine companies, and 1,788 drug stores throughout China. The Company actively develops a number of proprietary products for many uses including oncology, high blood pressure and the removal of toxins from food and animal feeds. For more information visit the Company's website at .

Cautionary Statement

This press release contains forward-looking statements concerning the Company's business and products. The Company's actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, obtaining regulatory approval for new products, the expected contribution of higher margin products, government support for rural health care, competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risks factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward- looking statements to reflect events or circumstances after the date of this release.





Three months ended Twelve Months ended

December 31, December 31,

2007 2006 2007 2006


Product sales 14,694,861 6,916,225 39,247,130 20,772,783

Medical formula sales 1,464,625 1,630,031 2,858,257 3,219,167

Total revenues 16,159,486 8,546,256 42,105,387 23,991,950

COST OF GOOD SOLD 11,678,186 5,106,769 29,708,088 15,017,100

GROSS PROFIT 4,481,300 3,439,487 12,397,299 8,974,850


Research and development 214,541 23,378 651,990 294,080

Selling, general and

administrative 895,619 481,094 3,343,058 1,565,288

Reverse acquisition -- 931,270

Total operating

expenses 1,110,160 504,472 3,995,048 2,790,638

INCOME FROM OPERATIONS 3,371,140 2,935,015 8,402,251 6,184,212

OTHER INCOME (EXPENSE), NET 11,819 (56,189) 15,423 (199,945)

INCOME BEFORE INCOME TAXES 3,382,959 2,878,827 8,417,674 5,984,267


PROVISION FOR INCOME TAXES 630,371 499,857 1,649,114 1,229,688


INTEREST 2,752,588 2,378,970 6,768,560 4,754,579

MINORITY INTEREST 26,012 33,295 94,658 33,295

NET INCOME 2,778,600 2,412,265 6,863,218 4,787,874


Foreign currency

translation adjustment 721,233 200,151 1,621,672 399,991

COMPREHENSIVE INCOME 3,499,833 2,612,416 8,484,890 5,187,865

Earning per share - basic $ 0.19 $ 0.32 $ 0.56 $ 0.65

Earning per share - diluted $ 0.17 $ 0.31 $ 0.50 $ 0.63

Weighted average number of

shares outstanding - basic 14,688,310 7,635,111 12,346,208 7,352,082

Weighted average number of

shares outstanding -

diluted 15,890,110 7,788,000 13,658,007 7,653,584



AS OF DECEMBER 31, 2007 AND 2006


2007 2006


Cash $5,767,774 $371,480

Accounts receivable, trade, net of

allowance for doubtful accounts

of $55,640 and $34,021 as of

December 31, 2007 and

December 31, 2006, respectively 13,626,347 7,034,911

Inventories 3,948,460 1,900,467

Advances to suppliers 5,983,277 3,126,100

Other current assets 81,221 42,136

Total current assets 29,407,079 12,475,094

EQUIPMENT, net 1,388,919 1,215,311


Deferred expenses 678,237 951,312

Intangible assets, net 1,166,003 128,882

Total other assets 1,844,240 1,080,194

Total assets $32,640,238 $14,770,599

L I A B I L I T I E S A N D S H A R E H O L D E R S' E Q U I T Y


Accounts payable, trade $76,907 $188,877

Other payables - related parties -- 30,000

Other payables and accrued

liabilities 70,343 23,265

Customer deposits 203,281 17,980

Taxes payable 468,184 295,902

Liquidated damages payable 44,003 44,003

Total liabilities 862,718 600,027

MINORITY INTEREST 893,337 908,480


Preferred stock, $0.0001 par value;

10,000,000 shares authorized,

111,649 and 2,340,000 shares

issued and outstanding

at December 31, 2007 and 2006,

respectively 11 234

Common stock, $0.0001 par value;

100,000,000 shares authorized,

14,821,641 and 8,160,000 shares

issued and outstanding

at December 31, 2007 and 2006,

respectively 1,482 816

Paid-in capital 12,560,078 4,396,971

Contribution receivable -- (961,500)

Statutory reserves 2,191,230 1,345,206

Retained earnings 14,008,587 7,979,242

Accumulated other comprehensive

income 2,122,795 501,123

Total shareholders' equity 30,884,183 13,262,092

Total liabilities and

shareholders' equity $32,640,238 $14,770,599




2007 2006



Net income $6,875,369 $4,787,874

Adjustments to reconcile net income

to cash

used in operating activities:

Minority interest (94,658) (33,295)

Depreciation and amortization 303,957 162,051

Bad debt expenses 18,495 --

Loss on sale of assets -- 15,732

Stock issued for services 179,400

SOURCE China Medicine Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Chinas 1-child policy could backfire on its elderly
2. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
3. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
4. Bridgetech Announces Addition of the Agency for Healthcare Research and Quality as Content Provider in its Development of a Healthcare Web Portal in China
5. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
6. China Bionanometer Industries Corporation Promotes New Cosmetics Product Line in China
7. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
8. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
9. Supplier Assessments to Help Buyers Identify Reliable China Exporters
10. Study shows lead-based paint problem isnt isolated to China
11. Bracco Announces Initiative to Save Children in China at 2007 Annual Meeting of CGI
Post Your Comments:
(Date:10/12/2015)... ... October 12, 2015 , ... To help ... its charitable donation to the National Breast Cancer Foundation. The National Breast Cancer ... breast cancer through early detection, education, and support services. , The annual campaign ...
(Date:10/12/2015)... ... October 12, 2015 , ... SQM Group ... a contact channel benchmarking study. Be a part of this insightful ... for improving customer experience, customer journey, contact channel execution and intelligence, workforce optimization, ...
(Date:10/12/2015)... ... ... Holcomb – Kreithen Plastic Surgery and MedSpa, PLLC (“Holcomb – Kreithen”), one of ... Surgery University,” an educational series of mini seminars covering aesthetic and plastic surgery options, ... Saturday, October 24, 2015. , The goal of the event is to provide hands-on ...
(Date:10/12/2015)... ... October 12, 2015 , ... The Asthma and ... Engagement Award by the Patient-Centered Outcomes Research Institute (PCORI) for a new project ... , The project, entitled “Training Patients with Asthma to Understand and Participate in ...
(Date:10/12/2015)... ... October 12, 2015 , ... International law firm Greenberg ... with the U.S. Biomedical Advanced Research and Development Authority (BARDA) reported to be ... ReCell® Autologous Cell Harvesting Device under a U.S. mass casualty preparedness program. ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... New York , October 12, 2015 ... (FMI) delivers key insights on the global vital signs monitoring ... Devices Market: Global Industry Analysis and Opportunity Assessment 2015-2025." The ... at a healthy CAGR of 9.5% and 9.2% in terms ... to factors, regarding which FMI offers major insights in detail ...
(Date:10/12/2015)... Oct. 12, 2015 Beginning October 1, 2015 ... Partner, the fastest growing practice management system for therapists, ... easily converts all patient diagnostic codes from the former ... --> --> Therapy Partner has ... mental health practitioners to easily understand the conversion to ...
(Date:10/12/2015)... , Oct. 12, 2015 Indivior PLC (LON: INDV) ... of Delaware granted the Company,s motion ... Abbreviated New Drug Application (ANDA) No. 205299 to market a ... and naloxone) Sublingual Film (CIII) in the United ... Since August 2013, Indivior has received Paragraph IV certifications ...
Breaking Medicine Technology: